Are you a print subscriber? Activate your account. By Garett Sloane - 3 min 8 sec ago By Ewan Larkin - 8 min 31 sec ago By ...

The companies will use Ascendis’ TransCon technology to develop therapies for metabolic and cardiovascular diseases ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at ...

Novo Nordisk's blockbuster drugs Ozempic and Wegovy have slimmed down Hollywood stars and millions of non-celebrities ...

JPMorgan placed shares of Novo Nordisk (NVO) on “Positive Catalyst Watch” ahead of the CagriSema REDEFINE 1 obesity data. The ...

James Manning / PA Images / Getty Images After rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its third-quarter sales fell short of ...

Novo Nordisk has shared promising results from a late-stage study ... The reesults come less than two months after Novo entered into a multi-year partnership worth $600m with NanoVation Therapeutics ...

Novo Nordisk’s blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter, sending shares 8.5% higher in early trade. Soaring popularity for its obesity drug has seen ...

Novo Nordisk, the company behind Ozempic and Wegovy, is now Europe's largest company as global demand for its drugs have soared. But the Danish pharmaceutical company's origins were motivated by ...

1 Day NVO 1.88% DJIA 0.68% S&P 500 -0.03% Health Care/Life Sciences 2.54% The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...

Novo Nordisk and Ascendis Pharma have agreed to collaborate in developing metabolic and cardiovascular therapies, among them a once-monthly glucagon-like peptide receptor agonist (GLP-1RA).

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...